Xiaobin Wu Sells 1,292 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 1,292 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $276.26, for a total value of $356,927.92. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaobin Wu also recently made the following trade(s):

• On Tuesday, June 16th, Xiaobin Wu sold 1,357 shares of BeOne Medicines stock. The shares were sold at an average price of $266.76, for a total transaction of $361,993.32.
• On Thursday, June 11th, Xiaobin Wu sold 626 shares of BeOne Medicines stock. The stock was sold at an average price of $261.20, for a total transaction of $163,511.20.
• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The shares were sold at an average price of $269.37, for a total transaction of $399,745.08.

BeOne Medicines Stock Performance

Shares of ONC opened at $279.89 on Friday. The company has a market capitalization of $30.71 billion, a PE ratio of 62.62 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company’s fifty day moving average price is $291.75 and its 200 day moving average price is $310.21.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The company had revenue of $1.51 billion during the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Analyst Ratings Changes

ONC has been the topic of a number of research analyst reports. Wall Street Zen lowered BeOne Medicines from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a report on Monday, April 20th. Wells Fargo & Company began coverage on BeOne Medicines in a research report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective for the company. Royal Bank Of Canada raised their price objective on shares of BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 2nd. Finally, Leerink Partners boosted their target price on shares of BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $390.00.

Institutional Investors Weigh In On BeOne Medicines

A number of institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE acquired a new position in BeOne Medicines in the 2nd quarter valued at approximately $67,657,000. Man Group plc acquired a new stake in shares of BeOne Medicines during the 2nd quarter worth approximately $59,031,000. Capital International Investors grew its holdings in shares of BeOne Medicines by 3.3% during the 3rd quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock worth $1,716,883,000 after purchasing an additional 161,052 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of BeOne Medicines during the second quarter valued at approximately $38,337,000. Finally, First Trust Advisors LP increased its position in shares of BeOne Medicines by 91.9% during the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after purchasing an additional 115,601 shares during the period. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.